CC BY
20
ABSTRACTS. PHYTOPHARM 2017
COMPLEX DATA IN HERBAL MEDICINAL PRODUCT RESEARCH: MULTI-STEP CLUSTERING OF PRECLINICAL DATA FOR A HERBAL COMBINATION
© Abdel-Aziz Heba1, Lorkowski Gerhardt2, Kelber Olaf3
1 Medical and Clinical Affairs Phytomedicines, Innovation and Development, Phytomedicines Supply
and Development Center, Bayer Consumer Health Division, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany;
2 GL Pharma Consulting Research & Development, Gauting, Germany;
3 Innovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health Division, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany
In functional gastrointestinal diseases (FGDs), a multitude of causes and likewise also targets for therapeutic interventions have been identified [1].
Multi-Step clustering is a standardized procedure to transfer heterogeneous pharmacological data, from different models, into effect size categories. Herbal combinations are an ideal candidate for the use of this newly described method. Therefore, STW 5 (Iberogast), a combination of nine herbal extracts, which has been proven to be effective in a large number of randomized controlled clinical studies [2], has been studied using this procedure.
This method is based on a step-wise cluster formation starting from the level of single tests up to the level of different pathomechanisms involved in the development of a certain disease e.g. FD, IBS.
The result is based on an overview on the pharmacological data of an herbal combiantion and its single components. The results on STW 5 and the contribution of the single constituents are evaluated and visualized by 2D histograms.
Thus, by making the allocation of specific actions to the different components of herbal combination products manageable, the results can also give support to the clinical use of the combination in patients with different symptom clusters.
References:
1. Allescher et al. 2006. Phytomedicine. 13:2-11.
2. Storr et al. 2016. Pharmakon. 4:356-364.
CROHN'S DISEASE IN AN EXPERIMENTAL MODEL: DATA ON THE HERBAL MEDICINAL PRODUCT STW 5 SUPPORT ITS POTENTIAL THERAPEUTIC USEFULNESS
© Mohamed T. Khayyal1, Walaa Wadie1, Dalaal Abdallah1, Mathias Schneider2, Olaf Kelber3, Thomas Efferth2, Heba Abdel-Aziz3
1 Cairo University, Faculty of Pharmacy, Department of Pharmacology, Cairo, Egypt;
2 Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Department of Pharmaceutical Biology, Mainz, Germany;
3 Bayer Consumer Health Division, Steigerwald Arzneimittelwerk GmbH, Innovation and Development Phytomedicines, Darmstadt, Germany
STW 5 is a standardized multi-component herbal mixture of hydro-alcoholic extracts of bitter candytuft, lemon balm, chamomile, caraway fruit, peppermint leaf, Angelica root, milk thistle, celandine herb, and licorice root. It has been used successfully clinically in functional dyspepsia (FD) [1] and irritable bowel syndrome (IBS) [2].
The present study was conducted to investigate mechanisms involved in a model of Crohn's disease, in the model of an 2,4,6-trinitrobenzenesulfonic acid (TNBS) induced colitis.
Colitis was induced by instilling TNBS in the colon of male Wistar rats under light ether anesthesia. In a prophylactic setting STW 5 was given orally for 1 week before induction of colitis and continued for 3 days after. In a curative setting, STW5 was given 48 h after colitis induction daily orally for 1 week. Rats were sacrificed 24 h after last
treatment. Colonic tissue was assessed macroscopically while homogenates and serum samples were used to assess inflammatory and oxidative stress parameters.
TNBS colitis led to severe ulcerative damage, inhibition of reduced glutathione and a rise in myeloperoxidase in colon homogenates. Pre-treatment with STW 5 antagonized such effects in a manner comparable to sulfasalazine.
The findings give supportive evidence for the potential usefulness of STW 5 in Crohn's disease.
References:
1. Schmulson MJ. 2008. Nature clinical practice gastroenterology & hepatology. 5:136-137.
2. Madisch A, et al. 2004. Aliment Pharmacol Ther. 19:271-279.
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy]
VOL. 15/2017/SUPPLEMENT 1
